Please login to the form below
FSG
This page shows the latest FSG news and features for those working in and with pharma, biotech and healthcare.
Retrophin rockets away as rare disease trial hits targets
Now, the company says a phase II trial of sparsentan in focal segmental glomerulosclerosis (FSG), a rare disease characterised by progressive scarring of the kidneys that often leads to kidney failure, ... Leerink analyst Joseph Schwartz has suggested
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US demand for COVID-19 antibody treatments rising fast
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- Havas Life Medicom and ARK lead at 2021 PM Society Digital Awards
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- Amgen’s Biosimilar Trends Report shows benefit of competition from biosimilars
- Cuttsy+Cuttsy awarded Gold accreditation by Investors in People
- Nudging someone in the right direction isn’t always easy – that’s where behavioural science comes in
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- David Hunt launches independent agency The Considered
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
- Amgen’s Biosimilar Trends Report shows benefit of competition from biosimilars
- Lucid Group celebrates a double win at Communiqué 2021
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
